RPP3A Antibody
Description
Rabphilin 3A (RPH3A) Antibody
Target Overview
Rabphilin 3A is a synaptic vesicle protein that interacts with Rab3A GTPase to regulate calcium-dependent exocytosis in neuroendocrine cells . Antibodies against RPH3A are primarily used in neuroscience research to study vesicle trafficking mechanisms.
Key Antibody Characteristics
Research Findings
-
Rabphilin 3A enhances calcium-dependent exocytosis independently of Rab3A .
-
Co-localizes with Rab3A on synaptic vesicles but requires distinct calcium-binding domains for activity .
RNA Polymerase III Subunit Antibodies (RPC3)
Target Overview
RNA polymerase III (RNAP III) antibodies target subunits of the RNAP III complex, notably RPC3, which are associated with systemic sclerosis (SSc). These autoantibodies correlate with disease severity and complications .
Clinical and Research Applications
Key Findings from SSc Studies
-
Intermolecular epitope spreading (ES) among RNAP III subunits correlates with interstitial lung disease biomarkers (e.g., surfactant protein-D) .
-
Intramolecular ES within RPC1 (a major RNAP III subunit) predicts renal crisis risk .
-
Antibody levels do not indicate disease severity but high titers increase diagnostic specificity for SSc .
Technical Validation in Proteomic Platforms
Reverse phase protein arrays (RPPA) frequently employ antibodies against targets like RPH3A and RNAP III subunits. Key validation metrics include:
Research Recommendations
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
To address the request for generating FAQs on "RPP3A Antibody" (interpreted here as PR3 antibodies in autoimmune research and Reverse Phase Protein Array [RPPA] methodologies), below is a structured collection of questions and methodological answers tailored for academic researchers. The content integrates insights from immunological studies on PR3-ANCA and RPPA technical workflows, emphasizing experimental rigor and data interpretation.
How can researchers address variability in PR3 antibody detection across experimental assays?
Variability arises from differences in epitope recognition, antibody glycosylation, and assay platforms. Strategies include:
-
Cross-validation: Compare results from ELISA, indirect immunofluorescence (IF), and Western blot .
-
Standardized controls: Use monoclonal antibodies (e.g., 4C3) with known epitope specificity (hydrophobic patch near PR3 active site) .
-
Neutrophil priming: Pre-treat cells with TNFα to enhance membrane PR3 expression before functional assays .
Data contradiction example:
What experimental designs are optimal for studying PR3 antibody-pathogen interactions?
-
In vitro models: Use TNFα-primed human neutrophils to assess PR3-ANCA-induced activation (e.g., CD11b upregulation, degranulation) .
-
Epitope mapping: Employ hydrogen-deuterium exchange mass spectrometry (HDX-MS) to localize antibody-binding regions on PR3 .
-
Fc receptor studies: Co-culture neutrophils with FcγRIIA/FcγRIIIB blockers to isolate PR3-mediated signaling .
Advanced tip:
Incorporate glycoengineered PR3 antibodies to dissect the role of Fc glycosylation in neutrophil activation .
How can RPPA enhance high-throughput analysis of PR3 antibody signaling pathways?
RPPA enables multiplexed protein quantification across hundreds of samples. Applications include:
-
Pathway profiling: Interrogate PR3-associated signaling nodes (e.g., PI3K/AKT, MAPK) in neutrophil lysates .
-
Post-translational modifications: Detect phosphorylation/acetylation events using validated antibodies .
Optimization steps:
-
Antody validation: Ensure specificity via knockdown/overexpression controls (e.g., HeLa vs. neutrophil lysates) .
-
Sample preparation: Use >50 mg tissue to achieve 1 mg/mL lysate concentration for reproducible spotting .
-
Data normalization: Include housekeeping proteins (e.g., β-actin) and reference cell lines (e.g., HUVEC) for inter-slide calibration .
What are common pitfalls in reconciling RPPA data with transcriptomic or genomic findings?
-
Temporal discordance: Protein levels (RPPA) may lag behind mRNA changes. Use longitudinal sampling.
-
Antibody cross-reactivity: Validate RPPA antibodies against unrelated proteases (e.g., elastase, cathepsin G) .
-
Pathway context: Combine RPPA with phospho-flow cytometry to resolve pathway crosstalk .
Example integration workflow:
-
Cluster RPPA data by signaling modules (e.g., apoptosis, proliferation).
-
Overlay differentially expressed genes from RNA-seq to identify regulatory hubs.
-
Validate candidates via siRNA knockdown in neutrophil models.
How to design a study investigating non-pathogenic vs. pathogenic PR3-ANCA?
-
Cohort selection: Enroll GPA patients in remission with persistent PR3-ANCA .
-
Functional assays: Compare neutrophil activation (ROS, adhesion molecules) induced by patient-derived IgG vs. non-activating mAbs (e.g., 4C3) .
-
Structural analysis: Solve crystal structures of PR3-antibody complexes to identify non-pathogenic epitopes .
Key finding: Non-pathogenic PR3-ANCA (e.g., 4C3) bind near the PR3 active site but lack Fc-mediated neutrophil activation .
